TRXB TRex Bio, Inc.
Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 2139097 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY—
TTM EPS YoY—
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE—
ROA—
ROIC (approx.)—
Asset turnover—
Leverage & solvency
Liabilities / assets15.8%
Debt / equity—
Current ratio7.58x
Interest coverage—
Cash quality & payout
Operating cash flow / net income—
Accruals ratio—
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 |
|---|---|---|---|---|---|---|
| Income statement | ||||||
| Revenue | — | — | — | — | — | — |
| R&D expense | $11.43M | — | — | $6.97M | — | — |
| SG&A expense | $2.49M | — | — | $1.74M | — | — |
| Operating income | -$13.92M | — | — | -$8.71M | — | — |
| Pretax income | -$13.15M | — | — | -$7.86M | — | — |
| Income tax | $88,000 | — | — | $0 | — | — |
| Net income | -$13.24M | -$13.09M | -$16.22M | -$7.86M | -$8.33M | -$9.39M |
| EPS (basic) | -10.06 | — | — | -7.58 | — | — |
| EPS (diluted) | -10.06 | — | — | -7.58 | — | — |
| Weighted avg. shares (diluted) | 1.32M | — | — | 1.04M | — | — |
| Balance sheet | ||||||
| Cash & equivalents | $16.81M | — | — | $25.79M | — | — |
| Short-term investments | $61.34M | — | — | — | — | — |
| Current assets | $79.85M | — | — | — | — | — |
| PP&E, net | $826,000 | — | — | — | — | — |
| Total assets | $88.75M | — | — | — | — | — |
| Current liabilities | $10.53M | — | — | — | — | — |
| Total liabilities | $14.03M | — | — | — | — | — |
| Shareholders' equity | -$134.11M | -$121.21M | -$108.26M | -$83.20M | -$75.51M | -$67.32M |
| Shares outstanding | 1.50M | — | — | — | — | — |
| Cash flow statement | ||||||
| Operating cash flow | — | — | — | — | — | — |
| Stock-based compensation | $178,000 | — | — | $129,000 | — | — |
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.